Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Frank Tacke, Tobias Puengel, Rohit Loomba, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 552-566
Closed Access | Times Cited: 152

Showing 1-25 of 152 citing articles:

Hepatic inflammatory responses in liver fibrosis
Linda Hammerich, Frank Tacke
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 633-646
Closed Access | Times Cited: 291
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2024), pp. gutjnl-330595
Open Access | Times Cited: 232
Fibroblast and myofibroblast activation in normal tissue repair and fibrosis
Fereshteh S. Younesi, Andrew Miller, Thomas H. Barker, et al.
Nature Reviews Molecular Cell Biology (2024) Vol. 25, Iss. 8, pp. 617-638
Closed Access | Times Cited: 122
PPARα/ACOX1 as a novel target for hepatic lipid metabolism disorders induced by per- and polyfluoroalkyl substances: An integrated approach
Yang Wang, Xi Ling, Shijun He, et al.
Environment International (2023) Vol. 178, pp. 108138-108138
Open Access | Times Cited: 70
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Maurizio Parola, Massimo Pinzani
Molecular Aspects of Medicine (2023) Vol. 95, pp. 101231-101231
Open Access | Times Cited: 57
Friend or foe? The elusive role of hepatic stellate cells in liver cancer
Bruno Cogliati, Chittampalli Yashaswini, Shuang Wang, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 647-661
Open Access | Times Cited: 55
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Shuang Wang, Scott L. Friedman
Science Translational Medicine (2023) Vol. 15, Iss. 716
Open Access | Times Cited: 51
Metabolic reprogramming in liver fibrosis
Paul Horn, Frank Tacke
Cell Metabolism (2024) Vol. 36, Iss. 7, pp. 1439-1455
Open Access | Times Cited: 51
Treating NASH by targeting peroxisome proliferator-activated receptors
Bart Staels, Laura Butruille, Sven Francque
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1302-1316
Open Access | Times Cited: 44
NAFLD and NASH: etiology, targets and emerging therapies
Shulin Wei, Lianzhou Wang, Paul C. Evans, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103910-103910
Closed Access | Times Cited: 43
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD
William P. Esler, David E. Cohen
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. 362-377
Open Access | Times Cited: 41
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
Juan Patricio Nogueira, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 20-28
Open Access | Times Cited: 41
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Xi Lu, Qingxing Xie, Xiaohui Pan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 39
Esculin inhibits hepatic stellate cell activation and CCl4-induced liver fibrosis by activating the Nrf2/GPX4 signaling pathway
Shuoxi Xu, Yonger Chen, Jindian Miao, et al.
Phytomedicine (2024) Vol. 128, pp. 155465-155465
Closed Access | Times Cited: 19
Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells
Hikmet Akkız, Robert K. Gieseler, Ali Canbay
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7873-7873
Open Access | Times Cited: 15
Hexokinase 2-mediated metabolic stress and inflammation burden of liver macrophages via histone lactylation in MASLD
Jinyang Li, Xiancheng Chen, Shiyu Song, et al.
Cell Reports (2025) Vol. 44, Iss. 3, pp. 115350-115350
Open Access | Times Cited: 2
Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions
Melissa Myint, Francesca Oppedisano, Valeria De Giorgi, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 22
Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
Scott L. Friedman
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 2, pp. 161-169
Open Access | Times Cited: 14
Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics
Salah Abdalrazak Alshehade
Clinics and Research in Hepatology and Gastroenterology (2024) Vol. 48, Iss. 7, pp. 102377-102377
Closed Access | Times Cited: 11
Crosstalk between fibroblasts and immunocytes in fibrosis: From molecular mechanisms to clinical trials
Xingpeng Di, Jiawei Chen, Ya Li, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti
Xie Wei, Jing Gan, Xiaodong Zhou, et al.
Cell Metabolism (2024) Vol. 36, Iss. 6, pp. 1269-1286.e9
Closed Access | Times Cited: 10
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell, Katharine Barnard‐Kelly, Tadej Battelino, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice
Zhaowei Zou, Xiu Liu, Jie Yu, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. 834-845
Closed Access | Times Cited: 8
NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
Simona Cernea
Life (2024) Vol. 14, Iss. 2, pp. 272-272
Open Access | Times Cited: 8
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Robert G. Gish, Jian‐Gao Fan, Zahra Dossaji, et al.
Hepatology International (2024)
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top